Recidivas del cáncer de mama ki 67 positivo en mujeres premenopáusicas, propuesta de diagnóstico oportuno
No hay miniatura disponible
Fecha
2016
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
El cáncer de mama representa el 30% de todas las neoplasias entre las mujeres, el índice más elevado se detecta en Europa y Norteamérica, en cuanto a edad y sexo es menos frecuentes en hombres y en mujeres jóvenes, su mayor incidencia se registra en mujeres de raza blanca. El cáncer de mama esporádico comprende el 90% de todos los casos. Entre los factores de riesgo asociados de canceres hereditarios podemos citar: antecedentes oncológicos familiares por la presencia de BRCA-1 y BRCA-2, p53 y PTEN. La reaparición del cáncer de mama en la misma zona que el tumor original sigue siendo el factor pronóstico independiente más potente para metástasis y muerte, incluso en pacientes que han vivido sanas durante mucho tiempo. La gravedad de una recidiva va a depender del tipo de tumor, su lugar de aparición, extensión y tiempo de evolución. Por lo cual la determinación del Ki67 es de utilidad pues es un factor de proliferación celular, es decir, un factor pronóstico. De esta manera se propone la siguiente pregunta científica: ¿Cómo contribuir a la reducción del riesgo de las recidivas asociadas al cáncer de mama Ki67 positivo en mujeres pre menopáusicas. El objetivo general será elaborar una guía de detección oportuna y el objetivo específico es evaluar que pacientes pre menopáusicas con cáncer de mama se encuentran en riesgo de recidiva tumoral, y diseñar los elementos constitutivos de guías de Practicas Organizacionales Requeridas. Actualmente las pautas del tratamiento adyuvante en el cáncer de mama se basan en las características tumorales o biomarcadores también llamados factores pronósticos y predictivos del cáncer de mama
The Breast cancer it represent the 30% of all cancers among women, the highest rate is found in Europe and North America, in terms of age and sex is less frequent in men and young women, whit highest incidence in white women. The Sporadic breast cancer comprises 90% of all cases. Among the associated risk factors of hereditary cancer we can include: family history of cancer by the presence of BRCA-1 and BRCA-2, p53 and PTEN. The recurrence of breast cancer in the same area as the original tumor is still the most powerful independent prognostic factor for developing a subsequent metastasis and death, even in healthy patients who have lived for a long time. The severity of a relapse will depend on the type of tumor, place of occurrence, extent and time course. Therefore the determination of Ki67 is useful because it is a factor of cellular proliferation, ie, prognostic factor. Thus proposes the following scientific question: How to contribute to reducing the risk of recurrence associated with breast cancer Ki67 positive in premenopausal women?. The overall objective will be to develop a guide for early detection and the specific objective is to assess that premenopausal patients with breast cancer are at risk of tumor recurrence, and designing the constituent elements of Organizational Practices Required guides. Currently the guidelines of adjuvant treatment in breast cancer is based on tumor characteristics or biomarkers also called prognostic and predictive factors of breast cancer.
The Breast cancer it represent the 30% of all cancers among women, the highest rate is found in Europe and North America, in terms of age and sex is less frequent in men and young women, whit highest incidence in white women. The Sporadic breast cancer comprises 90% of all cases. Among the associated risk factors of hereditary cancer we can include: family history of cancer by the presence of BRCA-1 and BRCA-2, p53 and PTEN. The recurrence of breast cancer in the same area as the original tumor is still the most powerful independent prognostic factor for developing a subsequent metastasis and death, even in healthy patients who have lived for a long time. The severity of a relapse will depend on the type of tumor, place of occurrence, extent and time course. Therefore the determination of Ki67 is useful because it is a factor of cellular proliferation, ie, prognostic factor. Thus proposes the following scientific question: How to contribute to reducing the risk of recurrence associated with breast cancer Ki67 positive in premenopausal women?. The overall objective will be to develop a guide for early detection and the specific objective is to assess that premenopausal patients with breast cancer are at risk of tumor recurrence, and designing the constituent elements of Organizational Practices Required guides. Currently the guidelines of adjuvant treatment in breast cancer is based on tumor characteristics or biomarkers also called prognostic and predictive factors of breast cancer.
Descripción
PDF
Palabras clave
Neoplasias de la mama, Recidivas, Premenopausia, Hospital SOLCA de Guayaquil, Cantón Guayaquil, Ecuador, Antígeno Ki-67